The Boston Globe, August 2nd, 2004
A Cambridge company searching for the secrets to human longevity, Elixir Pharmaceuticals, has suddenly seen its own time horizons shortened. The company's investors, it seems, don't have the patience to keep funding Elixir while it searches for the fountain of youth. They'd settle for a bottle of Evian and preferably sooner, rather than later. The 30-person biotech has been a media darling because of its ambitious goal: to leverage scientific breakthroughs that involved the ways yeast and worms age, all in the hopes of coming up with drugs to fight age-related diseases in humans. Elixir expect...
HighBeam Research, Free Preview: 'UNFOCUSED ELIXIR SEEKS NEW LIFE'... Full Membership required for unlimited access. Free 7-day trial.
Subscribers: HighBeam content is only available to HighBeam subscribers. Click the link above for more information.
